Head-to-head · WeighScore
Eden vs Nucific
The verdict
Eden takes it — 81.6/100 to 56.2/100.
Eden grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eden advertises lower-priced compounded bundles, but its offer and linked membership and warranty terms need to be reconciled before purchase.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Eden | Nucific |
|---|---|---|
| WeighScore | 81.6/100 | 56.2/100 |
| Grade | B− | C |
| Site position | #16 | #467 |
| Semaglutide | Advertised $99/mo bundle; linked membership terms conflict—confirm checkout | Not disclosed |
| Tirzepatide | Advertised $129/mo bundle; linked membership terms conflict—confirm checkout | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #16 · B−
FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.
Strengths
- Current compounded offer includes medication and support
- Homepage also advertises branded prescription pathways; eligibility and cost require confirmation
- Named pharmacy operation and partner network can be investigated
What to consider
- Linked membership terms describe a separate fee model
- Landing-page warranty and terms use different thresholds and conditions
- FDA warning history remains relevant; a new offer does not establish resolution
Site position #467 · C
Strengths
- Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
- Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
- Discloses that featured patients were compensated for their time
- Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
- Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalog
What to consider
- No price is published anywhere; every option is gated behind a three-minute quiz
- The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
- A BBB Accredited A+ claim is displayed without a link to the BBB profile
- No state list and no named pharmacy, only licensed U.S. pharmacies
- Before-and-after photographs are used alongside compensated testimonials
Featured provider
Eden
Eden scores 81.6/100 (B−). Eden advertises lower-priced compounded bundles, but its offer and linked membership and warranty terms need to be reconciled before purchase.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.